IgG4‐related lung disease progressing to respiratory failure

por Kunimatsu, Yusuke, Tani, Nozomi, Sato, Izumi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Publicado 2020

Drug‐induced interstitial lung disease associated with dasatinib coinciding with active tuberculosis

por Tani, Nozomi, Kunimatsu, Yusuke, Sato, Izumi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Publicado 2020

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer

por Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Sato, Izumi, Tani, Nozomi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Publicado 2020

Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study

por Tani, Nozomi, Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Sato, Izumi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Publicado 2021

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature

por Sato, Izumi, Mizuno, Hiroki, Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Tani, Nozomi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Publicado 2020

Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer

por Ogura, Yuri, Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Tani, Nozomi, Sato, Izumi, Hirose, Kazuki, Kato, Daishiro, Takeda, Takayuki
Publicado 2020

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study

por Morimoto, Kenji, Yamada, Tadaaki, Takumi, Chieko, Ogura, Yuri, Takeda, Takayuki, Onoi, Keisuke, Chihara, Yusuke, Taniguchi, Ryusuke, Yamada, Takahiro, Hiranuma, Osamu, Morimoto, Yoshie, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Publicado 2021

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features

por Tanimura, Keiko, Yamada, Tadaaki, Okada, Koutaroh, Nakai, Kunihiro, Horinaka, Mano, Katayama, Yuki, Morimoto, Kenji, Ogura, Yuri, Takeda, Takayuki, Shiotsu, Shinsuke, Ichikawa, Kosuke, Watanabe, Satoshi, Morimoto, Yoshie, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Taniguchi, Hirokazu, Yoneda, Kazue, Matoba, Satoaki, Sakai, Toshiyuki, Uehara, Hisanori, Yano, Seiji, Kusaba, Tetsuro, Katayama, Ryohei, Takayama, Koichi
Publicado 2022